Featured Research

from universities, journals, and other organizations

Promising Indiana University Lung Cancer Trial Enters New Phase

Date:
January 15, 2002
Source:
Indiana University
Summary:
The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results. The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results.

The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The procedure uses a 3-D computer generated grid system to more precisely map the location where therapy is directed. The patient is positioned in a specially fitted, lightweight body frame that limits mobility to ensure the precision of photon beams aimed at the tumor. "One advantage of the combined technology is that the risk of damaging healthy tissue despite such potent doses of radiation is reduced in comparison to conventional radiation."

"The results of the first phase were very encouraging and somewhat surprising," says Robert D. Timmerman, M.D., assistant professor of radiation oncology and the trial's principal investigator at the Indiana University Cancer Center. "We thought patients only would be able to tolerate lower doses since frail patients typically can't tolerate such rigorous treatment. To our surprise, we were able to increase dose levels without prohibitive toxicity."

This latest phase seeks to enroll 35 patients with early stage, non-small cell lung cancer whose tumors have not spread to lymph nodes or beyond and who have health conditions such as emphysema, severe heart disease, diabetes or a history of strokes, therefore making them poor candidates for surgery.

"Using a potent dose with assurance of reasonable safety to patients, we now want to measure the rate of controlling lung cancer and measure the patient's overall disease-free survival," Dr. Timmerman says.

Early stage lung cancer traditionally is treated with surgery, conventional radiation, or both. There is a 60 percent to 70 percent cure rate for early stage lung cancer in patients undergoing surgery, and a 20 percent to 30 percent cure rate for those treated with conventional radiation, which usually involves up to six weeks of daily radiation treatments.

In contrast, Phase 2 of this IU lung cancer trial delivers the entire treatment in three visits.

"We're optimistic this new therapy will bridge this large disparity giving patients a better chance of survival and a cure," notes Dr. Timmerman.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. ScienceDaily, 15 January 2002. <www.sciencedaily.com/releases/2002/01/020115074910.htm>.
Indiana University. (2002, January 15). Promising Indiana University Lung Cancer Trial Enters New Phase. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2002/01/020115074910.htm
Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. www.sciencedaily.com/releases/2002/01/020115074910.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins